UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On Wednesday, June 5, 2024, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) at 9:00 a.m., Eastern Time. As of the close of business on April 10, 2024, the record date for the Annual Meeting, there were 95,613,396 shares of common stock, par value 0.001 per share (the “Common Stock”), entitled to vote at the meeting.
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Third Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), to (i) increase the number of authorized shares of Common Stock from 150,000,000 to 300,000,000, which also has the effect of increasing the total number of authorized shares from 160,000,000 to 310,000,000, and (ii) delete the now outdated provisions that previously effected a reverse stock split (collectively, the “Amendment”).
On June 5, 2024, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Amendment, which became effective immediately upon such filing.
The foregoing description of the Amendment does not purport to be complete and is subject to and qualified in its entirety by reference to the Certificate of Amendment, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
Item 5.07. Submission of Matters to a Vote of Security Holders.
At the Annual Meeting, each of the Company’s director nominees was elected, a frequency of one year received a plurality of votes cast on Proposal 4 and each of the other proposals voted on were approved. The final voting results are set forth below.
| Votes For |
Votes Withheld |
Broker Non-Votes |
||||||||||
| Proposal 1. Election of Directors |
||||||||||||
| • Andrew Robbins |
67,815,951 | 8,532,411 | 3,198,670 | |||||||||
| • Peter Harwin |
51,730,466 | 24,617,896 | 3,198,670 | |||||||||
| Votes For |
Votes Against |
Abstentions | Broker Non-Votes | |||||
| Proposal 2. Ratification of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm |
79,462,753 | 79,190 | 5,089 | 0 | ||||
| Votes For |
Votes Against |
Abstentions | Broker Non-Votes | |||||
| Proposal 3. Advisory Vote on Executive Compensation |
69,604,506 | 6,731,575 | 12,281 | 3,198,670 | ||||
| 1 Year | 2 Years | 3 Years | Abstentions | Broker Non-Votes | ||||||
| Proposal 4. Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation |
75,185,417 | 7,763 | 1,119,915 | 35,267 | 0 |
In light of these voting results, the Company plans to hold future advisory votes on executive compensation annually until the next required vote on the frequency of such advisory votes, or until the Board of Directors of the Company otherwise determines that a different frequency is in the best interests of the Company and its stockholders.
| Votes For |
Votes Against |
Abstentions | Broker Non-Votes | |||||
| Proposal 5. Approval of an Amendment to the Certificate of Incorporation |
79,137,647 | 393,220 | 16,165 | 0 |
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 3.1 | Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of Cogent Biosciences, Inc. | |
| 104 | The cover page from the Company’s Current Report on Form 8-K formatted in Inline XBRL. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: June 5, 2024 | COGENT BIOSCIENCES, INC. | |||||
| By: | /s/ Evan Kearns | |||||
| Evan Kearns | ||||||
| Chief Legal Officer and Corporate Secretary | ||||||